226 related articles for article (PubMed ID: 34946547)
21. Differential effects of thapsigargin analogues on apoptosis of prostate cancer cells: complex regulation by intracellular calcium.
Dubois C; Vanden Abeele F; Sehgal P; Olesen C; Junker S; Christensen SB; Prevarskaya N; Møller JV
FEBS J; 2013 Nov; 280(21):5430-40. PubMed ID: 23927406
[TBL] [Abstract][Full Text] [Related]
22. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin.
Furuya Y; Lundmo P; Short AD; Gill DL; Isaacs JT
Cancer Res; 1994 Dec; 54(23):6167-75. PubMed ID: 7954463
[TBL] [Abstract][Full Text] [Related]
23. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer.
Chandran SS; Nan A; Rosen DM; Ghandehari H; Denmeade SR
Mol Cancer Ther; 2007 Nov; 6(11):2928-37. PubMed ID: 18025277
[TBL] [Abstract][Full Text] [Related]
24. Large scale purification of the SERCA inhibitor thapsigargin from Thapsia garganica L. roots using centrifugal partition chromatography.
Ollivier A; Grougnet R; Cachet X; Meriane D; Ardisson J; Boutefnouchet S; Deguin B
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():16-20. PubMed ID: 23537742
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.
Denmeade SR; Lin XS; Tombal B; Isaacs JT
Prostate; 1999 Jun; 39(4):269-79. PubMed ID: 10344216
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer.
Brennen WN; Rosen DM; Chaux A; Netto GJ; Isaacs JT; Denmeade SR
Prostate; 2014 Sep; 74(13):1308-19. PubMed ID: 25053236
[TBL] [Abstract][Full Text] [Related]
27. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells.
Jackisch C; Hahm HA; Tombal B; McCloskey D; Butash K; Davidson NE; Denmeade SR
Clin Cancer Res; 2000 Jul; 6(7):2844-50. PubMed ID: 10914733
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.
Jakobsen CM; Denmeade SR; Isaacs JT; Gady A; Olsen CE; Christensen SB
J Med Chem; 2001 Dec; 44(26):4696-703. PubMed ID: 11741487
[TBL] [Abstract][Full Text] [Related]
29. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin.
Lin XS; Denmeade SR; Cisek L; Isaacs JT
Prostate; 1997 Nov; 33(3):201-7. PubMed ID: 9365549
[TBL] [Abstract][Full Text] [Related]
30. Dual effect of thapsigargin on cell death in porcine aortic smooth muscle cells.
Chin TY; Lin HC; Kuo JP; Chueh SH
Am J Physiol Cell Physiol; 2007 Jan; 292(1):C383-95. PubMed ID: 17218371
[TBL] [Abstract][Full Text] [Related]
31. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
32. PSMA-Oriented Target Delivery of Novel Anticancer Prodrugs: Design, Synthesis, and Biological Evaluations of Oligopeptide-Camptothecin Conjugates.
Xu B; Zhou F; Yan MM; Cai DS; Guo WB; Yang YQ; Jia XH; Zhang WX; Li T; Ma T; Wang PL; Lei HM
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347770
[TBL] [Abstract][Full Text] [Related]
33. Localization and in-Vivo Characterization of
Andersen TB; Martinez-Swatson KA; Rasmussen SA; Boughton BA; Jørgensen K; Andersen-Ranberg J; Nyberg N; Christensen SB; Simonsen HT
Plant Physiol; 2017 May; 174(1):56-72. PubMed ID: 28275147
[TBL] [Abstract][Full Text] [Related]
34. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
Weidle UH; Tiefenthaler G; Georges G
Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.
Devkota L; Lin CM; Strecker TE; Wang Y; Tidmore JK; Chen Z; Guddneppanavar R; Jelinek CJ; Lopez R; Liu L; Hamel E; Mason RP; Chaplin DJ; Trawick ML; Pinney KG
Bioorg Med Chem; 2016 Mar; 24(5):938-956. PubMed ID: 26852340
[TBL] [Abstract][Full Text] [Related]
36. On the mechanism of histamine release induced by thapsigargin from Thapsia garganica L.
Patkar SA; Rasmussen U; Diamant B
Agents Actions; 1979 Apr; 9(1):53-7. PubMed ID: 88885
[TBL] [Abstract][Full Text] [Related]
37. Evidence for a role of the sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase in thapsigargin and Bcl-2 induced changes in Xenopus laevis oocyte maturation.
Kobrinsky EM; Kirchberger MA
Oncogene; 2001 Feb; 20(8):933-41. PubMed ID: 11314028
[TBL] [Abstract][Full Text] [Related]
38. Use of a temporary immersion bioreactor system for the sustainable production of thapsigargin in shoot cultures of
López CQ; Corral P; Lorrain-Lorrette B; Martinez-Swatson K; Michoux F; Simonsen HT
Plant Methods; 2018; 14():79. PubMed ID: 30202426
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the sarco/endoplasmic reticulum (ER) Ca
Sehgal P; Szalai P; Olesen C; Praetorius HA; Nissen P; Christensen SB; Engedal N; Møller JV
J Biol Chem; 2017 Dec; 292(48):19656-19673. PubMed ID: 28972171
[TBL] [Abstract][Full Text] [Related]
40. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
